| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 137, 486-494, Copyright © 1996 by Endocrine Society
ARTICLES |
N Di Simone, WF Crowley Jr, QF Wang, PM Sluss and AL Schneyer
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston 02114, USA.
Although ovarian cancer is the most common gynecological malignancy with a relatively poor 5-yr survival record, the mechanism(s) by which these tumors arise is not well understood. A role for inhibins and activins in regulating this transformation is suggested by the detection of circulating alpha or dimeric inhibin in some patients with ovarian cancer and by the alpha inhibin knockout mouse, in which development of gonadal tumors in 100% of homozygotes is associated with greatly elevated activin levels. To develop diagnostic tools with greater specificity for ovarian cancers, the present study was targeted at characterizing the biosynthetic capacity of the epithelial ovarian cancer cell lines from the American Type Culture Collection with respect to inhibin, activin, the related activin-binding protein follistatin (FS), and activin receptor type II. In addition, the functional capacity of this system was investigated by examining the ability of activin and FS to modulate cellular proliferation. All six cell lines contained abundant messenger RNA (mRNA) for activin receptor type II, but no inhibin alpha-subunit mRNA was detected in any cell line. Two cell lines contained mRNA for activin beta B-subunit (CaOV4 and SKOV3), one cell line contained beta A-subunit mRNA (SW626), and one cell line contained both (ES2); the latter also contained FS mRNA. FS mRNA was detected in another cell line (PA-1) that contained no detectable activin beta-subunit mRNA. Finally, one cell line (CaOV3) contained neither beta-subunit nor FS mRNA. Protein secretion was also examined. Consistent with the mRNA studies, the two cell lines containing FS mRNA secreted FS (PA-1 and ES2 cells), whereas three of the remaining lines secreted activin (A or B). In the cell line containing neither FS nor beta-subunit mRNA, no FS or activin could be detected. Finally, none of the cell lines secreted detectable immunoreactive inhibin. The effects of exogenous activin and FS on cellular proliferation were examined in these cell lines. No response was detected in the two cell lines that secreted FS (PA-1 and ES2). For the four cell lines not synthesizing FS, treatment with activin (1-100 ng/ml) resulted in an increase, whereas FS treatment (1-100 ng/ml) resulted in a decrease in cellular proliferation, as determined by [3H]thymidine incorporation. The response to activin correlated negatively with endogenous activin production, suggesting that autocrine activin production may be involved with cell proliferation. The differential expression and production of inhibin/activin subunits, activin receptors, and follistatin as well as the range of responses to exogenous activin among six ovarian epithelial cancer cell lines suggest that this family of hormones may be important in regulating cell proliferation in the ovary. Whether primary tumors have the same profile and the degree to which these results can be generalized to additional forms of ovarian cancer remain to be determined.
This article has been cited by other articles:
 |
|
 |
|
  T.-V. Do, L. A. Kubba, M. Antenos, A. W. Rademaker, C. D. Sturgis, and T. K. Woodruff The Role of Activin A and Akt/GSK Signaling in Ovarian Tumor Biology Endocrinology, August 1, 2008; 149(8): 3809 - 3816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yoshinaga, K. Yamashita, K. Mimori, F. Tanaka, H. Inoue, and M. Mori Activin A Causes Cancer Cell Aggressiveness in Esophageal Squamous Cell Carcinoma Cells Ann. Surg. Oncol., January 1, 2008; 15(1): 96 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Burdette, R. M. Oliver, V. Ulyanov, S. M. Kilen, K. E. Mayo, and T. K. Woodruff Ovarian Epithelial Inclusion Cysts in Chronically Superovulated CD1 and Smad2 Dominant-Negative Mice Endocrinology, August 1, 2007; 148(8): 3595 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al. A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection Cancer Res., March 1, 2007; 67(5): 2351 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Xu, H. Zhou, Q. Wang, N. Auersperg, and C. Peng Activin Receptor-Like Kinase 7 Induces Apoptosis through Up-Regulation of Bax and Down-Regulation of Xiap in Normal and Malignant Ovarian Epithelial Cell Lines Mol. Cancer Res., April 1, 2006; 4(4): 235 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Peters, J. Freund, and R. L. Ochs Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1605 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Steller, T. J. Shaw, B. C. Vanderhyden, and J.-F. Ethier Inhibin Resistance Is Associated with Aggressive Tumorigenicity of Ovarian Cancer Cells Mol. Cancer Res., January 1, 2005; 3(1): 50 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yoshinaga, H. Inoue, T. Utsunomiya, H. Sonoda, T. Masuda, K. Mimori, Y. Tanaka, and M. Mori N-Cadherin Is Regulated by Activin A and Associated with Tumor Aggressiveness in Esophageal Carcinoma Clin. Cancer Res., September 1, 2004; 10(17): 5702 - 5707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Pangas, A. W. Rademaker, D. A. Fishman, and T. K. Woodruff Localization of the Activin Signal Transduction Components in Normal Human Ovarian Follicles: Implications for Autocrine and Paracrine Signaling in the Ovary J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2644 - 2657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Dunfield, E. J. C. Dwyer, and M. W. Nachtigal TGF{beta}-Induced Smad Signaling Remains Intact in Primary Human Ovarian Cancer Cells Endocrinology, April 1, 2002; 143(4): 1174 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Fuller, E. T. Zumpe, S. Chu, P. Mamers, and H. G. Burger Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1395 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. You and F. E. Kruse Differential Effect of Activin A and BMP-7 on Myofibroblast Differentiation and the Role of the Smad Signaling Pathway Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 72 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Wildi, J Kleeff, H Maruyama, C A Maurer, M W Buchler, and M Korc Overexpression of activin A in stage IV colorectal cancer Gut, September 1, 2001; 49(3): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Duleba, T. Pehlivan, R. Carbone, and R. Z. Spaczynski Activin Stimulates Proliferation of Rat Ovarian Thecal-Interstitial Cells Biol Reprod, September 1, 2001; 65(3): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-C. Choi, S. K. Kang, C.-J. Tai, N. Auersperg, and P. C. K. Leung The Regulation of Apoptosis by Activin and Transforming Growth Factor-{beta} in Early Neoplastic and Tumorigenic Ovarian Surface Epithelium J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2125 - 2135. [Abstract] [Full Text]
|
|
|
|
|
|
N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]
|
|
|
|
|
|
T. Minegishi, T. Kameda, T. Hirakawa, K. Abe, M. Tano, and Y. Ibuki Expression of Gonadotropin and Activin Receptor Messenger Ribonucleic Acid in Human Ovarian Epithelial Neoplasms Clin. Cancer Res., July 1, 2000; 6(7): 2764 - 2770. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. McPherson, S. L. Mellor, H. Wang, L. W. Evans, N. P. Groome, and G. P. Risbridger Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines Endocrinology, November 1, 1999; 140(11): 5303 - 5309. [Abstract] [Full Text]
|
|
|
|
|
|
A. Delbaere, Y. Sidis, and A. L. Schneyer Differential Response to Exogenous and Endogenous Activin in a Human Ovarian Teratocarcinoma-Derived Cell Line (PA-1): Regulation by Cell Surface Follistatin Endocrinology, June 1, 1999; 140(6): 2463 - 2470. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Sidis,, T. Fujiwara,, L. Leykin,, K. Isaacson,, T. Toth,, and A. L. Schneyer Characterization of Inhibin/Activin Subunit, Activin Receptor, and Follistatin Messenger Ribonucleic Acid in Human and Mouse Oocytes: Evidence for Activin's Paracrine Signaling from Granulosa Cells to Oocytes Biol Reprod, October 1, 1998; 59(4): 807 - 812. [Abstract] [Full Text]
|
|
|
|
|
|
F. Petraglia, P. Florio, S. Luisi, R. Gallo, A. Gadducci, P. Viganò, A. M. Di Blasio, A. R. Genazzani, and W. Vale Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1194 - 1200. [Abstract] [Full Text]
|
|
|
|
|
|
C. K. Welt, G. Lambert-Messerlian, W. Zheng, W. F. Crowley Jr., and A. L. Schneyer Presence of Activin, Inhibin, and Follistatin in Epithelial Ovarian Carcinoma J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3720 - 3727. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
